SOUTH ORANGE, NJ, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.
Read the original:
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
Related Post
- Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - March 1st, 2024
- Gritstone bio Announces Workforce Reduction - March 1st, 2024
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 1st, 2024
- Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results - March 1st, 2024
- ProKidney to Participate in Jefferies Biotech on the Bay Summit - March 1st, 2024
- Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance - March 1st, 2024
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) - March 1st, 2024
- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - March 1st, 2024
- Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook - March 1st, 2024
- Prelude Therapeutics to Participate in Barclays Global Healthcare Conference - March 1st, 2024
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - March 1st, 2024
- Certara Reports Fourth Quarter 2023 Financial Results - March 1st, 2024
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - March 1st, 2024
- Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference - March 1st, 2024
- GENFIT Announces Revenues and Cash Position as of December 31, 2023 - March 1st, 2024
- Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - March 1st, 2024
- Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results - March 1st, 2024
- Spectral AI Appoints Peter M. Carlson as CEO - March 1st, 2024
- Arcutis to Present at the TD Cowen 44th Annual Health Care Conference - March 1st, 2024
- Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the... - February 21st, 2024
- PharmAla Data to be Published in ACS Chemical Neuroscience - February 21st, 2024
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge... - February 21st, 2024
- AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - February 21st, 2024
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting - February 21st, 2024
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference - February 21st, 2024
- Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00... - February 21st, 2024
- SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024 - February 21st, 2024
- NGM Bio to Participate in the Cowen 44th Annual Health Care Conference - February 21st, 2024
- NurExone’s Intellectual Property Portfolio Expands - February 21st, 2024
- PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market - February 21st, 2024
- Arvinas Announces Chief Financial Officer Transition - February 21st, 2024
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - February 21st, 2024
- DBV Technologies to Participate in Upcoming AAAAI 2024 Congress - February 21st, 2024
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 - February 21st, 2024
- Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. - February 21st, 2024
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 - February 21st, 2024
- PolTREG appoints Dan Shelly as Chief Business Development Officer - February 21st, 2024
- Sanofi: Information concerning the total number of voting rights and shares - January 2024 - February 21st, 2024
- Bavarian Nordic delivered record financial results in 2023 - February 21st, 2024
- Vistin Pharma ASA: Dividend of NOK 0.75 per share - January 14th, 2024
- HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status - January 14th, 2024
- Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31... - January 14th, 2024
- Key information relating to the cash dividend to be paid by Vistin Pharma ASA - January 14th, 2024
- QIAGEN N.V. to release results for Q4 2023 and hold webcast - January 14th, 2024
- Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries - January 14th, 2024
- TransCode Therapeutics Announces 1-for-40 Reverse Stock Split - January 14th, 2024
- Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference - January 14th, 2024
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study - January 14th, 2024
- Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting - January 14th, 2024
- Boehringer expands production site in Greece for new medicine - January 14th, 2024
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to... - January 14th, 2024
- Voting Rights and Shares Capital of the Company - January 14th, 2024
- Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom - January 14th, 2024
- CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - January 14th, 2024
- TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO - January 14th, 2024
- Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - January 14th, 2024
- Medicenna Announces Appointment of New Auditor - January 14th, 2024
- Axial Therapeutics to Present at Upcoming Conferences - January 6th, 2024
- NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million - January 6th, 2024
- Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea - January 6th, 2024
- SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,... - January 6th, 2024
- Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones - January 6th, 2024
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T... - January 6th, 2024
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders - January 6th, 2024
- Kriya Announces Gene Therapy Program for Thyroid Eye Disease - January 6th, 2024
- Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis - January 6th, 2024
- Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
- OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital - January 6th, 2024
- ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD) - January 6th, 2024
- BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to... - January 6th, 2024
- Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - January 6th, 2024
- PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development - January 6th, 2024
- Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - January 6th, 2024
- Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - January 6th, 2024
- Societal CDMO Reports Inducement Grants for New Staff - January 6th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 6th, 2024
- Shockwave Medical Reports First Quarter 2023 Financial Results - May 9th, 2023
